CellTrans, Inc.

Vertex remains bullish on prospects for developing curative, endogenous insulin-sparing cell therapies for type 1 diabetes, despite disappointing results unveiled on 28 March that led the Boston-based

Several companies are developing islet cell-based therapies for type 1 diabetes, and all face the same two problems: avoiding the host’s immune response to foreign tissue, and manufacturing at scale.

Cell and gene therapy developers have focused clinical programs around specific regulators in the absence of uniform global standards, with few sponsors successfully attempting approvals in both the U

Confidence in a potential curative treatment for Type 1 diabetes is growing after Vertex showed three people given its cell therapy, VX-880, lived without insulin injections for a year. New data fro